Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Two-dimensional combinatorial screening enables the bottom-up design of a microRNA-10b inhibitor.

Literature DB >> 24503738

Two-dimensional combinatorial screening enables the bottom-up design of a microRNA-10b inhibitor.

Sai Pradeep Velagapudi¹, Matthew D Disney.

Abstract

The RNA motifs that bind guanidinylated kanamycin A (G Kan A) and guanidinylated neomycin B (G Neo B) were identified via two-dimensional combinatorial screening (2DCS). The results of these studies enabled the "bottom-up" design of a small molecule inhibitor of oncogenic microRNA-10b.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 24503738 PMCID： PMC4040211 DOI： 10.1039/c3cc00173c

Source DB: PubMed Journal: Chem Commun (Camb) ISSN： 1359-7345 Impact factor: 6.222

24 in total

1. A Structural Basis for RNAminus signLigand Interactions.

Authors: Christine S. Chow; Felicia M. Bogdan
Journal: Chem Rev Date: 1997-08-05 Impact factor: 60.622

Review 2. Recent advances in developing small molecules targeting RNA.

Authors: Lirui Guan; Matthew D Disney
Journal: ACS Chem Biol Date: 2012-01-12 Impact factor: 5.100

3. Defining the RNA internal loops preferred by benzimidazole derivatives via 2D combinatorial screening and computational analysis.

Authors: Sai Pradeep Velagapudi; Steven J Seedhouse; Jonathan French; Matthew D Disney
Journal: J Am Chem Soc Date: 2011-06-09 Impact factor: 15.419

4. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma.

Authors: Lei Jin; Wang Lai Hu; Chen Chen Jiang; Jia Xu Wang; Chuan Chun Han; Ping Chu; Lin Jie Zhang; Rick F Thorne; James Wilmott; Richard A Scolyer; Peter Hersey; Xu Dong Zhang; Mian Wu
Journal: Proc Natl Acad Sci U S A Date: 2011-09-06 Impact factor: 11.205

5. Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model.

Authors: Meritxell Carrio; Gemma Arderiu; Connie Myers; Nancy J Boudreau
Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701

6. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model.

Authors: Li Ma; Ferenc Reinhardt; Elizabeth Pan; Jürgen Soutschek; Balkrishen Bhat; Eric G Marcusson; Julie Teruya-Feldstein; George W Bell; Robert A Weinberg
Journal: Nat Biotechnol Date: 2010-03-28 Impact factor: 54.908

7. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.

Authors: Li Ma; Julie Teruya-Feldstein; Robert A Weinberg
Journal: Nature Date: 2007-09-26 Impact factor: 49.962

8. Cellular uptake of aminoglycosides, guanidinoglycosides, and poly-arginine.

Authors: Nathan W Luedtke; Peter Carmichael; Yitzhak Tor
Journal: J Am Chem Soc Date: 2003-10-15 Impact factor: 15.419

9. Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1.

Authors: Jessica L Childs-Disney; Raman Parkesh; Masayuki Nakamori; Charles A Thornton; Matthew D Disney
Journal: ACS Chem Biol Date: 2012-11-07 Impact factor: 5.100

10. Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3.

Authors: Alexei Pushechnikov; Melissa M Lee; Jessica L Childs-Disney; Krzysztof Sobczak; Jonathan M French; Charles A Thornton; Matthew D Disney
Journal: J Am Chem Soc Date: 2009-07-22 Impact factor: 15.419

27 in total

Two-dimensional combinatorial screening enables the bottom-up design of a microRNA-10b inhibitor.

1. A Structural Basis for RNAminus signLigand Interactions.

Review 2. Recent advances in developing small molecules targeting RNA.

3. Defining the RNA internal loops preferred by benzimidazole derivatives via 2D combinatorial screening and computational analysis.

4. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma.

5. Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model.

6. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model.

7. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.

8. Cellular uptake of aminoglycosides, guanidinoglycosides, and poly-arginine.

9. Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1.

10. Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3.

Review 1. RNA Structural Differentiation: Opportunities with Pattern Recognition.

2. Differentiation and classification of RNA motifs using small molecule-based pattern recognition.

3. Bleomycin Can Cleave an Oncogenic Noncoding RNA.

Review 4. Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics.

Review 5. Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells.

6. Selective inhibition of miR-21 by phage display screened peptide.

Review 7. Structure based approaches for targeting non-coding RNAs with small molecules.

Review 8. Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Review 9. Targeting RNA in mammalian systems with small molecules.

10. A Macrocyclic Peptide Ligand Binds the Oncogenic MicroRNA-21 Precursor and Suppresses Dicer Processing.